Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

[1]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[2]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[3]  D. Kass,et al.  Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. , 2008, Cardiovascular research.

[4]  F. Hofmann,et al.  cGMP regulated protein kinases (cGK). , 2009, Handbook of experimental pharmacology.

[5]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE 5 inhibition in mice , 2009 .

[6]  J. Burnett,et al.  Novel Bifunctional Natriuretic Peptides as Potential Therapeutics* , 2008, Journal of Biological Chemistry.

[7]  D. Kass,et al.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. , 2008, Cellular signalling.

[8]  G. Wensing,et al.  Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58‐2667) in Healthy Male Volunteers , 2008, Journal of clinical pharmacology.

[9]  Anindita Das,et al.  Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β* , 2008, Journal of Biological Chemistry.

[10]  Lan Zhao,et al.  Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[11]  J. Bos,et al.  PKA and Epac1 regulate endothelial integrity and migration through parallel and independent pathways. , 2008, European journal of cell biology.

[12]  W. Durán,et al.  Nitroglycerin-Induced S-nitrosylation and Desensitization of Soluble Guanylyl Cyclase Contribute to Nitrate Tolerance , 2008, Circulation research.

[13]  M. Kramer,et al.  Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: A pilot study , 2008, Respirology.

[14]  P. dos Santos,et al.  Conditioning the heart induces formation of signalosomes that interact with mitochondria to open mitoKATP channels. , 2008, American journal of physiology. Heart and circulatory physiology.

[15]  K. Hirata,et al.  Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: the possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[16]  D. Kass,et al.  Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil , 2008, Journal of Pharmacology and Experimental Therapeutics.

[17]  M. Lohse,et al.  Real-time monitoring of phosphodiesterase inhibition in intact cells. , 2008, Cellular signalling.

[18]  J. Burnett,et al.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. , 2008, Journal of the American College of Cardiology.

[19]  S. Hazen,et al.  Augmented inducible nitric oxide synthase expression and increased NO production reduce sepsis-induced lung injury and mortality in myeloperoxidase-null mice. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[20]  S. Zahler,et al.  Atrial Natriuretic Peptide Protects against Histamine-Induced Endothelial Barrier Dysfunction in Vivo , 2008, Molecular Pharmacology.

[21]  Elena Alekseeva,et al.  Epac/Rap and PKA are novel mechanisms of ANP‐induced Rac‐mediated pulmonary endothelial barrier protection , 2008, Journal of cellular physiology.

[22]  James B. Mitchell,et al.  Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy , 2008, Circulation.

[23]  C. Des Rosiers,et al.  Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency , 2008, Proceedings of the National Academy of Sciences.

[24]  Rodolphe Fischmeister,et al.  Spatiotemporal Dynamics of β-Adrenergic cAMP Signals and L-Type Ca2+ Channel Regulation in Adult Rat Ventricular Myocytes: Role of Phosphodiesterases , 2008, Circulation research.

[25]  F. Veglia,et al.  Sildenafil improves the alveolar-capillary function in heart failure patients. , 2008, International journal of cardiology.

[26]  A. Pries,et al.  Negative-Feedback Loop Attenuates Hydrostatic Lung Edema via a cGMP-Dependent Regulation of Transient Receptor Potential Vanilloid 4 , 2008, Circulation research.

[27]  D. Kass,et al.  High-Dose Folic Acid Pretreatment Blunts Cardiac Dysfunction During Ischemia Coupled to Maintenance of High-Energy Phosphates and Reduces Postreperfusion Injury , 2008, Circulation.

[28]  X. Loyer,et al.  CONSTITUTIVE NITRIC OXIDE SYNTHASES IN THE HEART FROM HYPERTROPHY TO FAILURE , 2008, Clinical and experimental pharmacology & physiology.

[29]  T. Renné,et al.  Role of vasodilator-stimulated phosphoprotein in cGMP-mediated protection of human pulmonary artery endothelial barrier function. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[30]  T. Münzel,et al.  Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. , 2008, Antioxidants & redox signaling.

[31]  D. Webb,et al.  Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients , 2008, Journal of hypertension.

[32]  David A. Kass,et al.  Tackling heart failure in the twenty-first century , 2008, Nature.

[33]  A. Lin,et al.  Atrial Natriuretic Peptide-initiated cGMP Pathways Regulate Vasodilator-stimulated Phosphoprotein Phosphorylation and Angiogenesis in Vascular Endothelium* , 2008, Journal of Biological Chemistry.

[34]  E. Kranias,et al.  Reduced Phospholamban Phosphorylation Is Associated With Impaired Relaxation in Left Ventricular Myocytes From Neuronal NO Synthase–Deficient Mice , 2008, Circulation research.

[35]  S. Oparil,et al.  Atrial Natriuretic Peptide Inhibits Transforming Growth Factor β–Induced Smad Signaling and Myofibroblast Transformation in Mouse Cardiac Fibroblasts , 2008, Circulation research.

[36]  F. Coppi,et al.  Sildenafil improves endothelial function in patients with pulmonary hypertension. , 2008, Pulmonary pharmacology & therapeutics.

[37]  Myung H. Park.  Advances in diagnosis and treatment in patients with pulmonary arterial hypertension , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[38]  C. Wainwright,et al.  Phospholipid chlorohydrin induces leukocyte adhesion to ApoE-/- mouse arteries via upregulation of P-selectin. , 2008, Free radical biology & medicine.

[39]  A. Bonev,et al.  Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors , 2008, Proceedings of the National Academy of Sciences.

[40]  L. Lerman,et al.  The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans , 2008, Hypertension.

[41]  Anindita Das,et al.  Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. , 2007, American journal of physiology. Heart and circulatory physiology.

[42]  M. Mitchell,et al.  Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects , 2006, Journal of clinical pharmacology.

[43]  M. Curran,et al.  Sildenafil: a review of its use in pulmonary arterial hypertension. , 2008, Drugs.

[44]  J. Rosado,et al.  Natriuretic peptides in vascular physiology and pathology. , 2008, International review of cell and molecular biology.

[45]  Michael V. Cohen,et al.  cGMP signalling in pre- and post-conditioning: the role of mitochondria. , 2008, Cardiovascular research.

[46]  D. Hess,et al.  Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. , 2007, American journal of respiratory and critical care medicine.

[47]  J. Chen,et al.  Enhanced nitric oxide-mediated chemoreceptor inhibition and altered cyclic GMP signaling in rat carotid body following chronic hypoxia. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[48]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[49]  D. Kass,et al.  Phosphodiesterase type 5: expanding roles in cardiovascular regulation. , 2007, Circulation research.

[50]  F. Vandeput,et al.  Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes* , 2007, Journal of Biological Chemistry.

[51]  F. Ruschitzka,et al.  Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia , 2007, Heart.

[52]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .

[53]  J. P. Brennan,et al.  Cysteine Redox Sensor in PKGIa Enables Oxidant-Induced Activation , 2007, Science.

[54]  M. Coggins,et al.  Nitric Oxide in the Pulmonary Vasculature , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[55]  M. Mongillo,et al.  Protein Kinase G Phosphorylates Cav1.2 α1c and β2 Subunits , 2007, Circulation research.

[56]  D. Collen,et al.  Soluble Guanylate Cyclase-&agr;1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia , 2007, Circulation.

[57]  N. Westerhof,et al.  Nitric oxide and cardiac function. , 2007, Life sciences.

[58]  I. Grupp,et al.  eNOS Deficient Mice Develop Progressive Cardiac Hypertrophy with Altered Cytokine and Calcium Handling Protein Expression , 2007, Cardiovascular Toxicology.

[59]  S. Pikkarainen,et al.  Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses , 2007, Journal of cellular physiology.

[60]  M. Guazzi,et al.  The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. , 2007, Current medicinal chemistry.

[61]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[62]  D. Kass,et al.  Phosphodiesterase regulation of nitric oxide signaling. , 2007, Cardiovascular research.

[63]  R. Mueller,et al.  NO mobilizes intracellular Zn2+ via cGMP/PKG signaling pathway and prevents mitochondrial oxidant damage in cardiomyocytes. , 2007, Cardiovascular research.

[64]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[65]  L. Lerman,et al.  Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans , 2007, Circulation.

[66]  Michael V. Cohen,et al.  Signaling pathways in ischemic preconditioning , 2007, Heart Failure Reviews.

[67]  M. Robson,et al.  Global Improvement of Vascular Function and Redox State With Low-Dose Folic Acid: Implications for Folate Therapy in Patients With Coronary Artery Disease , 2007, Circulation.

[68]  J. Stasch,et al.  Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure , 2007, Hypertension.

[69]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[70]  E. Ongini,et al.  Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type‐1 diabetic mice , 2007, British journal of pharmacology.

[71]  J. Beavo,et al.  Differential Regulation of Endothelial Cell Permeability by cGMP via Phosphodiesterases 2 and 3 , 2007, Circulation research.

[72]  O. Osadchii.  Myocardial Phosphodiesterases and Regulation of Cardiac Contractility in Health and Cardiac Disease , 2007, Cardiovascular Drugs and Therapy.

[73]  Clint L. Miller,et al.  Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart , 2007, Circulation research.

[74]  J. Klinger.  The nitric oxide/cGMP signaling pathway in pulmonary hypertension. , 2007, Clinics in chest medicine.

[75]  G. Kojda,et al.  Lack of Endothelial Nitric Oxide Synthase–Derived Nitric Oxide Formation Favors Hypertrophy in Adult Ventricular Cardiomyocytes , 2007, Hypertension.

[76]  A. Monopoli,et al.  The Nitric Oxide-Donating Pravastatin Derivative, NCX 6550 [(1S-[1α(βS*, δS*), 2α, 6α, 8β-(R*), 8aα]]-1,2,6,7,8,8a-Hexahydro-β, δ, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphtalene-heptanoic Acid 4-(Nitrooxy)butyl Ester)], Reduces Splenocyte Adhesion and Reactive Oxygen Species Generation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[77]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[78]  S. Lohmann,et al.  Cyclic GMP-dependent Protein Kinase Iα Attenuates Necrosis and Apoptosis Following Ischemia/Reoxygenation in Adult Cardiomyocyte* , 2006, Journal of Biological Chemistry.

[79]  R. Fischmeister,et al.  Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. , 2006, Circulation research.

[80]  J. Stasch,et al.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.

[81]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[82]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[83]  H. Hori,et al.  Functional Characterization of Two Nucleotide-binding Sites in Soluble Guanylate Cyclase* , 2006, Journal of Biological Chemistry.

[84]  S. Abman,et al.  BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats , 2006, Neonatology.

[85]  J. Molkentin,et al.  Regulation of cardiac hypertrophy by intracellular signalling pathways , 2006, Nature Reviews Molecular Cell Biology.

[86]  M. Silberbach,et al.  Natriuretic Peptides and Nitric Oxide Stimulate cGMP Synthesis in Different Cellular Compartments , 2006, The Journal of general physiology.

[87]  Lubo Zhang,et al.  Chronic hypoxic decreases in soluble guanylate cyclase protein and enzyme activity are age dependent in fetal and adult ovine carotid arteries. , 2006, Journal of applied physiology.

[88]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[89]  R. Saraiva,et al.  Nitric oxide signaling in the cardiovascular system: implications for heart failure , 2006, Current opinion in cardiology.

[90]  D. Cooper,et al.  A Specific Pattern of Phosphodiesterases Controls the cAMP Signals Generated by Different Gs-Coupled Receptors in Adult Rat Ventricular Myocytes , 2006, Circulation research.

[91]  C. Tsai,et al.  Purification and Characterization , 2006 .

[92]  B. Casadei,et al.  Are myocardial eNOS and nNOS involved in the beta-adrenergic and muscarinic regulation of inotropy? A systematic investigation. , 2006, Cardiovascular research.

[93]  D. Nagel,et al.  Role of Nuclear Ca2+/Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival , 2006, Circulation research.

[94]  J. Monti,et al.  Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[95]  E. Antunes,et al.  Protective Effects of BAY 41-2272 (sGC Stimulator) on Hypertension, Heart, and Cardiomyocyte Hypertrophy Induced by Chronic L-NAME Treatment in Rats , 2006, Journal of cardiovascular pharmacology.

[96]  N. Ali,et al.  Thiol oxidation inhibits nitric oxide-mediated pulmonary artery relaxation and guanylate cyclase stimulation. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[97]  J. Klinger,et al.  Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. , 2006, Experimental cell research.

[98]  M. Zaccolo,et al.  Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway , 2006, Circulation research.

[99]  E. Hirsch,et al.  Phosphoinositide 3‐kinaseγ (PI3Kγ) controls L‐type calcium current (ICa,L) through its positive modulation of type‐3 phosphodiesterase (PDE3) , 2006 .

[100]  W. Seeger,et al.  Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.

[101]  Steven P Jones,et al.  The ubiquitous role of nitric oxide in cardioprotection. , 2006, Journal of molecular and cellular cardiology.

[102]  T. Lincoln,et al.  Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. , 2006, Frontiers in bioscience : a journal and virtual library.

[103]  A. Malik,et al.  Signaling mechanisms regulating endothelial permeability. , 2006, Physiological reviews.

[104]  F. Hofmann,et al.  Function of cGMP-dependent protein kinases as revealed by gene deletion. , 2006, Physiological reviews.

[105]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[106]  E. Ongini,et al.  A novel nitric oxide‐releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression 1 , 2005, Journal of thrombosis and haemostasis : JTH.

[107]  R. Bolli,et al.  Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS. , 2005, American journal of physiology. Heart and circulatory physiology.

[108]  S. Abman,et al.  Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[109]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[110]  R. Fischmeister,et al.  Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. , 2005, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[111]  中島 務,et al.  マウス蝸牛における cyclic GMP-dependent protein kinase-I の発現 , 2005 .

[112]  M. Marletta,et al.  Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP, and GTP. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[113]  J. Downey,et al.  Protein Kinase G Transmits the Cardioprotective Signal From Cytosol to Mitochondria , 2005, Circulation research.

[114]  M. Mocanu,et al.  Preconditioning the diabetic heart: the importance of Akt phosphorylation. , 2005, Diabetes.

[115]  J. Tidball,et al.  Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. , 2005, Human molecular genetics.

[116]  C. Brophy,et al.  Role of the small heat shock proteins in regulating vascular smooth muscle tone. , 2005, Journal of the American College of Surgeons.

[117]  Katherine Lanning,et al.  Dynamic Association of Nitric Oxide Downstream Signaling Molecules with Endothelial Caveolin-1 in Rat Aorta , 2005, Journal of Pharmacology and Experimental Therapeutics.

[118]  M. Yanagisawa,et al.  Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. , 2005, The Journal of clinical investigation.

[119]  A. Zeiher,et al.  Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. , 2005, Cardiovascular research.

[120]  D. Maurice.  Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. , 2005, Frontiers in bioscience : a journal and virtual library.

[121]  D. Irwin,et al.  Direct ANP inhibition of hypoxia-induced inflammatory pathways in pulmonary microvascular and macrovascular endothelial monolayers. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[122]  K. Aaronson,et al.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.

[123]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[124]  L. Storme,et al.  Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[125]  K. Aaronson,et al.  Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.

[126]  H. Weiss,et al.  Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. , 2005, European journal of pharmacology.

[127]  P. Ping,et al.  Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. , 2005, American journal of physiology. Heart and circulatory physiology.

[128]  K. Mori,et al.  C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. , 2005, Journal of the American College of Cardiology.

[129]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[130]  J. Beavo,et al.  Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[131]  D. Maurice,et al.  Vascular Endothelial Cell Cyclic Nucleotide Phosphodiesterases and Regulated Cell Migration: Implications in Angiogenesis , 2005, Molecular Pharmacology.

[132]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[133]  U. Walter,et al.  Signal transduction by cGMP in heart , 1991, Basic Research in Cardiology.

[134]  H. Drexler,et al.  Systemic and regional vascular effects of atrial natriuretic peptide in a rat model of chronic heart failure , 1987, Basic Research in Cardiology.

[135]  N. Morrell,et al.  cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[136]  Peng Wang,et al.  Per-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with IkappaB proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[137]  F. Hofmann,et al.  cGMP-Dependent Protein Kinase Mediates NO- but not Acetylcholine-Induced Dilations in Resistance Vessels In Vivo , 2004, Hypertension.

[138]  D. Koesling,et al.  NO activation of guanylyl cyclase , 2004, The EMBO journal.

[139]  S. Fazio,et al.  Tadalafil in primary pulmonary arterial hypertension. , 2004, Annals of internal medicine.

[140]  J. Stypmann,et al.  Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. , 2004, Cardiovascular research.

[141]  S. Hazen,et al.  Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[142]  O. V. Evgenov,et al.  Soluble Guanylate Cyclase Activator Reverses Acute Pulmonary Hypertension and Augments the Pulmonary Vasodilator Response to Inhaled Nitric Oxide in Awake Lambs , 2004, Circulation.

[143]  W. Seeger,et al.  Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. , 2004, Journal of the American College of Cardiology.

[144]  A. Csiszar,et al.  Premature death and age-related cardiac dysfunction in male eNOS-knockout mice. , 2004, Journal of molecular and cellular cardiology.

[145]  B. Wong,et al.  Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings , 2004, Neuromuscular Disorders.

[146]  L. Silengo,et al.  PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects , 2004, Cell.

[147]  E. Ongini,et al.  Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[148]  K. Mori,et al.  Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. , 2004, Endocrinology.

[149]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[150]  Aleksander S Popel,et al.  A theoretical model of nitric oxide transport in arterioles: frequency- vs. amplitude-dependent control of cGMP formation. , 2004, American Journal of Physiology. Heart and Circulatory Physiology.

[151]  M. Wheeler,et al.  Functional nitric oxide synthase mislocalization in cardiomyopathy. , 2004, Journal of molecular and cellular cardiology.

[152]  G. Baxter,et al.  Autocrine and paracrine actions of natriuretic peptides in the heart. , 2004, Pharmacology & therapeutics.

[153]  A. Vaandrager,et al.  Signalling by cGMP-dependent protein kinases , 1996, Molecular and Cellular Biochemistry.

[154]  S. Kaufman.  Some metabolic relationships between biopterin and folate: Implications for the “methyl trap hypothesis” , 1991, Neurochemical Research.

[155]  V. Viswanathan.  Role of cyclic GMP-dependent protein kinase type II in the brain , 2004 .

[156]  S. Kuo,et al.  YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. , 2004, Cardiovascular research.

[157]  Y. Hirata.  [Natriuretic peptide]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[158]  U. Walter,et al.  Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase. , 2004, Acta biochimica Polonica.

[159]  R. Pilz,et al.  This Review Is Part of a Thematic Series on Cyclic Gmp–generating Enzymes and Cyclic Gmp–dependent Signaling, Which Includes the following Articles: Regulation of Nitric Oxide–sensitive Guanylyl Cyclase Cyclic Gmp Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and , 2022 .

[160]  J. Kostis,et al.  Overview of phosphodiesterase 5 inhibition in erectile dysfunction. , 2003, The American journal of cardiology.

[161]  F. Hofmann,et al.  Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3′,5′-Cyclic Monophosphate–Dependent Protein Kinase , 2003 .

[162]  S. Archer,et al.  Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension , 2003, Circulation.

[163]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[164]  M. Mendelsohn,et al.  Dimerization of cGMP-dependent protein kinase 1alpha and the myosin-binding subunit of myosin phosphatase: role of leucine zipper domains. , 2003, Cellular signalling.

[165]  M. Mcgoon,et al.  Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. , 2003, Mayo Clinic proceedings.

[166]  J. Downey,et al.  Preconditioning the myocardium: from cellular physiology to clinical cardiology. , 2003, Physiological reviews.

[167]  Hisham S. Elbatarny,et al.  Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. , 2003, Molecular pharmacology.

[168]  J. Beavo,et al.  Regulation of Nitric Oxide–Sensitive Guanylyl Cyclase Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and Function of Membrane Guanylyl Cyclase Receptors, With a Focus on GC-A Cyclic GMP–Dependent Protein Kinases and the Cardiovascular System: Insights F , 2003 .

[169]  U. Bachrach,et al.  The opposing effects of endothelin-1 and C-type natriuretic peptide on apoptosis of neonatal rat cardiac myocytes. , 2003, European journal of pharmacology.

[170]  R. Fischmeister,et al.  Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following β2‐adrenergic stimulation of ICa,L in frog ventricular myocytes , 2003, The Journal of physiology.

[171]  R. Kloner,et al.  Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. , 2003, Circulation.

[172]  A. Shoukas,et al.  Nitric Oxide Regulation of Myocardial Contractility and Calcium Cycling: Independent Impact of Neuronal and Endothelial Nitric Oxide Synthases , 2003 .

[173]  D. Harrison,et al.  Interactions of Peroxynitrite, Tetrahydrobiopterin, Ascorbic Acid, and Thiols , 2003, Journal of Biological Chemistry.

[174]  S. Javadov,et al.  Ischaemic Preconditioning Inhibits Opening of Mitochondrial Permeability Transition Pores in the Reperfused Rat Heart , 2003, The Journal of physiology.

[175]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[176]  C. Rembold,et al.  Heat induced HSP20 phosphorylation without increased cyclic nucleotide levels in swine carotid media , 2003, BMC Physiology.

[177]  Steven M Holland,et al.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.

[178]  K. Nakao,et al.  Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. , 2003, American journal of physiology. Heart and circulatory physiology.

[179]  U. Walter,et al.  Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[180]  E. Ashley,et al.  Cardiac Neuronal Nitric Oxide Synthase Isoform Regulates Myocardial Contraction and Calcium Handling , 2003, Circulation research.

[181]  P. Caroni,et al.  Downregulation of Cytoskeletal Muscle LIM Protein by Nitric Oxide: Impact on Cardiac Myocyte Hypertrophy , 2003, Circulation.

[182]  Jieli Chen,et al.  Nitric Oxide Enhances Angiogenesis via the Synthesis of Vascular Endothelial Growth Factor and cGMP After Stroke in the Rat , 2003, Circulation research.

[183]  J. Stasch,et al.  Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure , 2003, Circulation.

[184]  U. Walter,et al.  Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. , 2003, Biochemical pharmacology.

[185]  R. Ritchie,et al.  Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. , 2003, Cardiovascular research.

[186]  J. Balligand,et al.  Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice , 2003, The Journal of physiology.

[187]  K. Omori,et al.  cGMP-Phosphodiesterase Activity Is Up-regulated in Response to Pressure Overload of Rat Ventricles , 2003, Bioscience, biotechnology, and biochemistry.

[188]  G. Jackson,et al.  Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. , 2002, International journal of cardiology.

[189]  M. Maclean,et al.  Increased expression of the cGMP‐inhibited cAMP‐specific (PDE3) and cGMP binding cGMP‐specific (PDE5) phosphodiesterases in models of pulmonary hypertension , 2002, British journal of pharmacology.

[190]  B. Yoder,et al.  Developmental changes in nitric oxide synthase isoform expression and nitric oxide production in fetal baboon lung. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[191]  G. Fiskum,et al.  The Role of Tetrahydrobiopterin in the Regulation of Neuronal Nitric-oxide Synthase-generated Superoxide* , 2002, The Journal of Biological Chemistry.

[192]  P. K. Moore,et al.  Pharmacology and potential therapeutic applications of nitric oxide‐releasing non‐steroidal anti‐inflammatory and related nitric oxide‐donating drugs , 2002, British journal of pharmacology.

[193]  C. López-Otín,et al.  Activation of the mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 by the nitric oxide-cGMP-cGMP-dependent protein kinase axis regulates the expression of matrix metalloproteinase 13 in vascular endothelial cells. , 2002, Molecular pharmacology.

[194]  K. Okumura,et al.  Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure , 2002, Heart and Vessels.

[195]  H. Drexler,et al.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[196]  J. Stasch,et al.  NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle , 2002, British journal of pharmacology.

[197]  K. Maruyama,et al.  Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes , 2002, European Respiratory Journal.

[198]  T. Rabelink,et al.  Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate , 2002, Diabetologia.

[199]  E. Bell,et al.  Natriuretic peptide receptor-B in adult rat ventricle is predominantly confined to the nonmyocyte population. , 2002, American journal of physiology. Heart and circulatory physiology.

[200]  S. Verma,et al.  Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. , 2002, American journal of physiology. Heart and circulatory physiology.

[201]  S. Archer,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .

[202]  R. Marthan,et al.  Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. , 2002, Biochemical pharmacology.

[203]  D. Tilley,et al.  Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. , 2002, Molecular pharmacology.

[204]  Jonathan Goodfellow,et al.  Folic Acid Improves Endothelial Function in Coronary Artery Disease via Mechanisms Largely Independent of Homocysteine Lowering , 2002, Circulation.

[205]  A. Shah,et al.  Role of cyclic GMP‐dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes , 2002, The Journal of physiology.

[206]  U. Zabel,et al.  Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide , 2002, Nature Cell Biology.

[207]  E. Ehler,et al.  Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice , 2002, Heart.

[208]  J. Joseph,et al.  The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. , 2002, The Biochemical journal.

[209]  U. Walter,et al.  Effects of Angiotensin II Infusion on the Expression and Function of NAD(P)H Oxidase and Components of Nitric Oxide/cGMP Signaling , 2002, Circulation research.

[210]  J. West,et al.  YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. , 2002, Biochemical and biophysical research communications.

[211]  J. Pollock,et al.  Birth upregulates nitric oxide synthase activity in the porcine lung. , 2002, Life sciences.

[212]  D. Heistad,et al.  Regression of Atherosclerosis in Monkeys Reduces Vascular Superoxide Levels , 2002, Circulation research.

[213]  G. Kojda,et al.  Effect of Hypercholesterolemia on Expression and Function of Vascular Soluble Guanylyl Cyclase , 2002, Circulation.

[214]  T. Ashikaga,et al.  Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). , 2002, Biochemical pharmacology.

[215]  F. Hofmann,et al.  cGMP-Dependent Protein Kinase I Mediates the Negative Inotropic Effect of cGMP in the Murine Myocardium , 2002, Circulation research.

[216]  C. Trautwein,et al.  Gene Transfer of cGMP-Dependent Protein Kinase I Enhances the Antihypertrophic Effects of Nitric Oxide in Cardiomyocytes , 2002, Hypertension.

[217]  R. Zechner,et al.  Myocardial Contractile Function and Heart Rate in Mice With Myocyte-Specific Overexpression of Endothelial Nitric Oxide Synthase , 2001, Circulation.

[218]  G. Kojda,et al.  The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. , 2001, Free radical biology & medicine.

[219]  D. Koesling,et al.  Guanylyl Cyclase/PSD-95 Interaction , 2001, The Journal of Biological Chemistry.

[220]  B. Bussolati,et al.  Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. , 2001, The American journal of pathology.

[221]  M. Andreassi,et al.  Up‐regulation of ‘clearance’ receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones , 2001, European journal of heart failure.

[222]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[223]  M. D. de Bold,et al.  The physiological and pathophysiological modulation of the endocrine function of the heart. , 2001, Canadian journal of physiology and pharmacology.

[224]  R. Newcombe,et al.  Folate Improves Endothelial Function in Coronary Artery Disease: An Effect Mediated by Reduction of Intracellular Superoxide? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[225]  F. Hofmann,et al.  Molecular Determinants of the Interaction between the Inositol 1,4,5-Trisphosphate Receptor-associated cGMP Kinase Substrate (IRAG) and cGMP Kinase Iβ* 210 , 2001, The Journal of Biological Chemistry.

[226]  R. Fischmeister,et al.  Cyclic GMP regulation of the L‐type Ca2+ channel current in human atrial myocytes , 2001, The Journal of physiology.

[227]  B. Schoser,et al.  Soluble guanylyl cyclase is localized at the neuromuscular junction in human skeletal muscle , 2001, Neuroreport.

[228]  C. Roberts,et al.  Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. , 2001, Cellular signalling.

[229]  D. Harrison,et al.  Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.

[230]  R K Jain,et al.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[231]  C. Napoli,et al.  Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[232]  Roger Y. Tsien,et al.  Spatiotemporal dynamics of guanosine 3′,5′-cyclic monophosphate revealed by a genetically encoded, fluorescent indicator , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[233]  J. Russell,et al.  Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs , 2001, Pediatric pulmonology.

[234]  E. Degerman,et al.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. , 2001, Progress in nucleic acid research and molecular biology.

[235]  D. Koesling,et al.  Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. , 2001, The Journal of biological chemistry.

[236]  D. Irwin,et al.  Atrial natriuretic peptide blockade exacerbates high altitude pulmonary edema in endotoxin-primed rats. , 2001, High altitude medicine & biology.

[237]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition. , 2001, The Biochemical journal.

[238]  T. Meinertz,et al.  Vasodilator-Stimulated Phosphoprotein Serine 239 Phosphorylation as a Sensitive Monitor of Defective Nitric Oxide/cGMP Signaling and Endothelial Dysfunction , 2000, Circulation research.

[239]  S. Ogawa,et al.  Calmodulin Kinases II and IV and Calcineurin Are Involved in Leukemia Inhibitory Factor–Induced Cardiac Hypertrophy in Rats , 2000, Circulation research.

[240]  M. Gatzoulis,et al.  Sildenafil in primary pulmonary hypertension. , 2000, The New England journal of medicine.

[241]  F. Hofmann,et al.  Mechanisms of NO/cGMP-dependent vasorelaxation. , 2000, Circulation research.

[242]  R. Johns,et al.  eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[243]  M. Yano,et al.  Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum. , 2000, American journal of physiology. Heart and circulatory physiology.

[244]  N. Brindle,et al.  Vasodilator-Stimulated Phosphoprotein Is Involved in Stress-Fiber and Membrane Ruffle Formation in Endothelial Cells , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[245]  N. Galiè.  Medical therapy of pulmonary arterial hypertension. , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.

[246]  U. Walter,et al.  Regulation of Human Endothelial Cell Focal Adhesion Sites and Migration by cGMP-dependent Protein Kinase I* , 2000, The Journal of Biological Chemistry.

[247]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[248]  R. Bing,et al.  The effect of aspirin and two nitric oxide donors on the infarcted heart in situ. , 2000, Life sciences.

[249]  T. Rabelink,et al.  Folic acid reverts dysfunction of endothelial nitric oxide synthase. , 2000, Circulation research.

[250]  M. Emerson,et al.  Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. , 2000, European journal of pharmacology.

[251]  Y. Zou,et al.  Ca2+/Calmodulin-dependent Kinase II and Calcineurin Play Critical Roles in Endothelin-1-induced Cardiomyocyte Hypertrophy* , 2000, The Journal of Biological Chemistry.

[252]  D. Burkhoff,et al.  PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor) Defective Regulation in Failing Hearts , 2000, Cell.

[253]  M. Paul,et al.  Acute blood pressure effects of YC‐1‐induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats , 2000, British journal of pharmacology.

[254]  C. Rembold,et al.  cGMP‐mediated phosphorylation of heat shock protein 20 may cause smooth muscle relaxation without myosin light chain dephosphorylation in swine carotid artery , 2000, The Journal of physiology.

[255]  T. Nakayama,et al.  Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. , 2000, Circulation research.

[256]  A. Shah,et al.  Paracrine and autocrine effects of nitric oxide on myocardial function. , 2000, Pharmacology & therapeutics.

[257]  K. Takeda,et al.  Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. , 2000, Journal of the American College of Cardiology.

[258]  Y. Zhao,et al.  Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. , 2000, Biochemistry.

[259]  G. Neubauer,et al.  Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Iβ , 2000, Nature.

[260]  P. Huang,et al.  Modulation of mouse cardiac function in vivo by eNOS and ANP. , 2000, American journal of physiology. Heart and circulatory physiology.

[261]  H. Schmidt,et al.  Endothelial Nitric-oxide Synthase (Type III) Is Activated and Becomes Calcium Independent upon Phosphorylation by Cyclic Nucleotide-dependent Protein Kinases* , 2000, The Journal of Biological Chemistry.

[262]  M. Bernareggi,et al.  MYOCARDIAL PROTECTION BY THE NITRODERIVATIVE OF ASPIRIN, NCK 4016: IN VIVO AND IN VITRO EXPERIMENT IN RABBIT , 2000 .

[263]  J. Molkentin,et al.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[264]  H. Piper,et al.  Apoptosis induction by nitric oxide in adult cardiomyocytes via cGMP-signaling and its impairment after simulated ischemia. , 2000, Cardiovascular research.

[265]  E. Marbán,et al.  Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. , 2000, Circulation.

[266]  R. Ma,et al.  Regulation of Ca(2+)-activated K(+) channels by multifunctional Ca(2+)/calmodulin-dependent protein kinase. , 2000, American journal of physiology. Renal physiology.

[267]  M. Bernareggi,et al.  Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit. , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.

[268]  T. L. Le Cras,et al.  Developmental changes in endothelial nitric oxide synthase expression and activity in ovine fetal lung. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[269]  S. Klöss,et al.  Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. , 2000, Hypertension.

[270]  T. Horio,et al.  Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. , 2000, Hypertension.

[271]  Y. Zhao,et al.  A molecular basis for nitric oxide sensing by soluble guanylate cyclase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[272]  C. Lugnier,et al.  Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel. , 1999, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[273]  N. Blau,et al.  Serine 19 of Human 6-Pyruvoyltetrahydropterin Synthase Is Phosphorylated by cGMP Protein Kinase II* , 1999, The Journal of Biological Chemistry.

[274]  D. Sawyer,et al.  Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. , 1999, Circulation research.

[275]  G. Radda,et al.  Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. , 1999, Journal of molecular and cellular cardiology.

[276]  R. Johns,et al.  Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[277]  U. Zabel,et al.  Downloaded from http://circres.ahajournals.org / by guest on February 20, 2013Downregulation of Soluble Guanylyl Cyclase in Young and Aging Spontaneously Hypertensive Rats , 2022 .

[278]  P. Huang,et al.  Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[279]  M. Ito,et al.  Effects of the phosphorylation of myosin phosphatase by cyclic GMP-dependent protein kinase. , 1999, Cellular signalling.

[280]  J. Kastelein,et al.  Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. , 1999, Circulation.

[281]  P. B. Snyder,et al.  Isolation, expression and analysis of splice variants of a human Ca2+/calmodulin-stimulated phosphodiesterase (PDE1A). , 1999, Cellular signalling.

[282]  K. Sadhu,et al.  Differential Expression of the Cyclic GMP-stimulated Phosphodiesterase PDE2A in Human Venous and Capillary Endothelial Cells , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[283]  T. LeJemtel,et al.  Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. , 1999, Journal of the American College of Cardiology.

[284]  O. Carretero,et al.  Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. , 1999, Hypertension.

[285]  J. Bronzwaer,et al.  Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. , 1999, Circulation.

[286]  R. Mrowka,et al.  Enhanced blood pressure variability in eNOS knockout mice. , 1999, Hypertension.

[287]  E. Lakatta,et al.  Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. , 1999, Circulation research.

[288]  F. Lezoualc’h,et al.  Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L‐type Ca2+ current in rat ventricular myocytes , 1999, British journal of pharmacology.

[289]  G. Kojda,et al.  Regulation of basal myocardial function by NO. , 1999, Cardiovascular research.

[290]  D. Bredt,et al.  Nitric oxide synthase in cardiac sarcoplasmic reticulum. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[291]  P. Huang,et al.  The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.

[292]  W. Goebel,et al.  Differential expression of , 1999 .

[293]  M. Shichiri,et al.  Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[294]  Jesse D. Roberts,et al.  Adenovirus-mediated Gene Transfer of cGMP-dependent Protein Kinase Increases the Sensitivity of Cultured Vascular Smooth Muscle Cells to the Antiproliferative and Pro-apoptotic Effects of Nitric Oxide/cGMP* , 1998, The Journal of Biological Chemistry.

[295]  K. Takeuchi,et al.  Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses. , 1998, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[296]  O. Carretero,et al.  Role of nNOS in blood pressure regulation in eNOS null mutant mice. , 1998, Hypertension.

[297]  S. Eddahibi,et al.  Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats , 1998, British journal of pharmacology.

[298]  H. Drexler,et al.  Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. , 1998, Journal of the American College of Cardiology.

[299]  H. Granger,et al.  Protein Kinase G Mediates Vascular Endothelial Growth Factor-induced Raf-1 Activation and Proliferation in Human Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[300]  R. Hotchkiss,et al.  Nitric oxide inhibits stress-induced endothelial cell apoptosis. , 1998, Critical care medicine.

[301]  K. Takeuchi,et al.  Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin. , 1998, The Journal of pharmacology and experimental therapeutics.

[302]  Y. Hirata,et al.  Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. , 1998, Chest.

[303]  P. Huang,et al.  Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. , 1998, The Journal of clinical investigation.

[304]  P. Klatt,et al.  Defective smooth muscle regulation in cGMP kinase I‐deficient mice , 1998, The EMBO journal.

[305]  N. Hill,et al.  Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. , 1998, Journal of applied physiology.

[306]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[307]  W. Abraham,et al.  Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.

[308]  R. Busse,et al.  Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. , 1998, Cardiovascular research.

[309]  P. Huang,et al.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.

[310]  H. Granger,et al.  Nitric Oxide Is an Upstream Signal of Vascular Endothelial Growth Factor-induced Extracellular Signal-regulated Kinase½ Activation in Postcapillary Endothelium* , 1998, The Journal of Biological Chemistry.

[311]  J. Kastelein,et al.  5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. , 1998, Circulation.

[312]  R. Cardinal,et al.  Sympathetic functions in NG‐nitro‐L‐arginine‐methylester‐induced hypertension: modulation by the renin‐angiotensin system , 1998, Journal of hypertension.

[313]  E. Porteri,et al.  Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. , 1998, Hypertension.

[314]  H. S. Kim,et al.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[315]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[316]  W. Linz,et al.  Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. , 1997, Hypertension.

[317]  J. Balligand,et al.  Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[318]  P. Trindade,et al.  Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. , 1997, Cardiovascular research.

[319]  P. Huang,et al.  Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. , 1997, Circulation research.

[320]  G. O. Carrier,et al.  Nitrovasodilators relax mesenteric microvessels by cGMP-induced stimulation of Ca-activated K channels. , 1997, The American journal of physiology.

[321]  G. Garcı́a-Cardeña,et al.  Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. , 1997, The American journal of pathology.

[322]  I. Yuhanna,et al.  Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. , 1997, The American journal of physiology.

[323]  H. Rasmussen,et al.  Cyclic Nucleotide-dependent Vasorelaxation Is Associated with the Phosphorylation of a Small Heat Shock-related Protein* , 1997, The Journal of Biological Chemistry.

[324]  N. Bishopric,et al.  Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. , 1996, The Journal of biological chemistry.

[325]  T. Noll,et al.  Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells. , 1997, The American journal of physiology.

[326]  L. Tariosse,et al.  Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. , 1997, Journal of molecular and cellular cardiology.

[327]  A. Yao,et al.  Cardiac inducible nitric oxide synthase negatively modulates myocardial function in cultured rat myocytes. , 1997, The American journal of physiology.

[328]  D. Heitjan,et al.  Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. , 1996, Circulation.

[329]  L. Ruilope,et al.  Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs. , 1996, American journal of hypertension.

[330]  M. Ueda,et al.  The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model. , 1996, American journal of respiratory and critical care medicine.

[331]  M. Horiuchi,et al.  Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. , 1996, Circulation research.

[332]  E. Martin,et al.  Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets. , 1996, Chest.

[333]  J. Hoidal,et al.  Regulation of Ca(2+)-activated K+ channels in pulmonary vascular smooth muscle cells: role of nitric oxide. , 1996, Journal of applied physiology.

[334]  F. Hofmann,et al.  Protein Phosphatase 2A Is Essential for the Activation of Ca2+-activated K+ Currents by cGMP-dependent Protein Kinase in Tracheal Smooth Muscle and Chinese Hamster Ovary Cells* , 1996, The Journal of Biological Chemistry.

[335]  J C Gingell,et al.  Sildenafil, a novel effective oral therapy for male erectile dysfunction. , 1996, British journal of urology.

[336]  S. Snyder,et al.  Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[337]  A. Shah,et al.  Paracrine modulation of heart cell function by endothelial cells. , 1996, Cardiovascular research.

[338]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[339]  S. Lohmann,et al.  N-terminal Myristoylation Is Required for Membrane Localization of cGMP-dependent Protein Kinase Type II (*) , 1996, The Journal of Biological Chemistry.

[340]  W. Paulus,et al.  Myocardial contractile response to nitric oxide and cGMP. , 1996, Circulation.

[341]  T. Ogihara,et al.  Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. , 1996, Hypertension.

[342]  R. Johns,et al.  Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. , 1996, The American journal of physiology.

[343]  G. Kojda,et al.  Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. , 1996, Circulation research.

[344]  W. K. Sonnenburg,et al.  Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases (*) , 1995, The Journal of Biological Chemistry.

[345]  A. Dominiczak,et al.  Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. , 1995, Hypertension.

[346]  D. Garbers,et al.  Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide , 1995, Nature.

[347]  U. Walter,et al.  Expression of cGMP-dependent protein kinase I and phosphorylation of its substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of different origin. , 1995, Circulation research.

[348]  T. MacDonald,et al.  Influence of basal nitric oxide secretion on cardiac function in man. , 1995, British journal of clinical pharmacology.

[349]  C. Harteneck,et al.  A Variant of the α2 Subunit of Soluble Guanylyl Cyclase Contains an Insert Homologous to a Region within Adenylyl Cyclases and Functions as a Dominant Negative Protein (*) , 1995, The Journal of Biological Chemistry.

[350]  T. Risler,et al.  Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. , 1995, Experimental nephrology.

[351]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[352]  R. Fischmeister,et al.  Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. , 1995, Molecular pharmacology.

[353]  U. Walter,et al.  The proline‐rich focal adhesion and microfilament protein VASP is a ligand for profilins. , 1995, The EMBO journal.

[354]  S. M. de la Monte,et al.  Constitutive endothelial nitric oxide synthase gene expression is regulated during lung development. , 1995, The American journal of physiology.

[355]  C. Lowenstein,et al.  Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1 beta and IFN-gamma. , 1995, The American journal of physiology.

[356]  O. Smithies,et al.  Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension , 1995, Science.

[357]  D. Atsma,et al.  cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. , 1995, Circulation research.

[358]  R. Johns,et al.  Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia. , 1994, The American journal of physiology.

[359]  J. Newman,et al.  Changes in pulmonary vascular tone during exercise. Effects of nitric oxide (NO) synthase inhibition, L-arginine infusion, and NO inhalation. , 1994, The Journal of clinical investigation.

[360]  E. Arnold,et al.  Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. , 1994, The American journal of physiology.

[361]  S. Archer,et al.  Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[362]  S. Soifer,et al.  Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs. , 1994, The Journal of clinical investigation.

[363]  S. Snyder,et al.  Nitric oxide synthase type I and type III gene expression are developmentally regulated in rat lung. , 1994, The American journal of physiology.

[364]  E. Lakatta,et al.  8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. , 1994, Circulation research.

[365]  J. Stamler,et al.  Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. , 1994, Circulation.

[366]  R. Cohen,et al.  Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle , 1994, Nature.

[367]  R. Trifiletti,et al.  Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. , 1994, Biology of the neonate.

[368]  K. Macnaul,et al.  Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. , 1993, Biochemical and Biophysical Research Communications - BBRC.

[369]  R. Johns,et al.  Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung. , 1993, Journal of applied physiology.

[370]  D. Harrison,et al.  Hypercholesterolemia increases endothelial superoxide anion production. , 1993, The Journal of clinical investigation.

[371]  E. Weitzberg,et al.  Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxin shock. , 1993, European journal of pharmacology.

[372]  T. Tsuda,et al.  Cytokine‐induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells , 1993, FEBS letters.

[373]  R. Rossaint,et al.  Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction without impairing gas exchange. , 1993, Journal of applied physiology.

[374]  G. Hedenstierna,et al.  Inhaled Nitric Oxide Selectively Reverses Human Hypoxic Pulmonary Vasoconstriction without Causing Systemic Vasodilation , 1993, Anesthesiology.

[375]  R. Rossaint,et al.  Inhaled nitric oxide for the adult respiratory distress syndrome. , 1993, The New England journal of medicine.

[376]  Richard E. White,et al.  Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation , 1993, Nature.

[377]  C. Frampton,et al.  Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. , 1993, The Journal of clinical endocrinology and metabolism.

[378]  P. Smits,et al.  Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. , 1993, Circulation.

[379]  E. Schiffrin,et al.  Divergent regulation of atrial natriuretic factor receptors in high-output heart failure. , 1992, The American journal of physiology.

[380]  W. Schmitz,et al.  Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea‐pig hearts , 1992, British journal of pharmacology.

[381]  R. Zatz,et al.  Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. , 1992, Hypertension.

[382]  H. E. von der Leyen,et al.  Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. , 1992, Arzneimittel-Forschung.

[383]  H. Saito,et al.  NG-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone? , 1992, Circulation research.

[384]  M. Kinoshita,et al.  Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. , 1991, Journal of the American College of Cardiology.

[385]  G. Schultz,et al.  Molecular cloning and expression of a new α‐subunit of soluble guanylyl cyclase Interchangeability of the α‐subunits of the enzyme , 1991 .

[386]  D. Garbers,et al.  A new form of guanylyl cyclase is preferentially expressed in rat kidney. , 1990, Biochemistry.

[387]  B. Brüne,et al.  Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. , 1990, European journal of biochemistry.

[388]  A. Takeshita,et al.  Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure. , 1990, Circulation.

[389]  K. Nakao,et al.  Rat Brain Natriuretic Peptide: Isolation From Rat Heart and Tissue Distribution , 1990, Hypertension.

[390]  K. Nakao,et al.  Human brain natriuretic peptide, a novel cardiac hormone , 1990, The Lancet.

[391]  K. Nakao,et al.  Isolation and sequence determination of human brain natriuretic peptide in human atrium , 1990, FEBS letters.

[392]  H. Itoh,et al.  Synthesis of atrial natriuretic polypeptide in human failing hearts. Evidence for altered processing of atrial natriuretic polypeptide precursor and augmented synthesis of beta-human ANP. , 1988, The Journal of clinical investigation.

[393]  F. Hofmann,et al.  Cyclic GMP-dependent protein kinase phosphorylates phospholamban in isolated sarcoplasmic reticulum from cardiac and smooth muscle. , 1988, The Biochemical journal.

[394]  W. Forssmann,et al.  Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. , 1988, Circulation.

[395]  R. Hansen,et al.  Purification of calmodulin-stimulated cyclic nucleotide phosphodiesterase by monoclonal antibody affinity chromatography. , 1988, Methods in enzymology.

[396]  L. Raeymaekers,et al.  The (Ca2+ ‐Mg2+)‐ATPases of the Plasma Membrane and of the Endoplasmic Reticulum in Smooth Muscle Cells and Their Regulation , 1988, Journal of cardiovascular pharmacology.

[397]  L. Ignarro,et al.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[398]  L. Ignarro,et al.  Endothelium‐Derived Relaxing Factor From Pulmonary Artery and Vein Possesses Pharmacologic and Chemical Properties Identical to Those of Nitric Oxide Radical , 1987, Circulation research.

[399]  Andrew,et al.  Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. , 1986, The Journal of clinical investigation.

[400]  A. Olivera,et al.  Atrial Natriuretic Peptide , 1986, The Lancet.

[401]  B. Katzung,et al.  Biphasic Contractions Induced by Milrinone at Low Temperature in Ferret Ventricular Muscle: Role of the Sarcoplasmic Reticulum and Transmembrane Calcium Influx , 1986, Circulation research.

[402]  F. Murad,et al.  Soluble guanylate cyclase from rat lung exists as a heterodimer. , 1986, The Journal of biological chemistry.

[403]  G. Reeder,et al.  Atrial natriuretic peptide elevation in congestive heart failure in the human. , 1986, Science.

[404]  R. Sharma,et al.  Calmodulin and Ca2+-dependent phosphorylation and dephosphorylation of 63-kDa subunit-containing bovine brain calmodulin-stimulated cyclic nucleotide phosphodiesterase isozyme. , 1986, The Journal of biological chemistry.

[405]  J. Seidman,et al.  Biosynthesis and secretion of proatrial natriuretic factor by cultured rat cardiocytes. , 1985, Science.

[406]  I. Tikkanen,et al.  PLASMA ATRIAL NATRIURETIC PEPTIDE IN CARDIAC DISEASE AND DURING INFUSION IN HEALTHY VOLUNTEERS , 1985, The Lancet.

[407]  J. Gwathmey,et al.  The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret , 1985, British journal of pharmacology.

[408]  A. D. de Bold,et al.  Atrial natriuretic factor: a hormone produced by the heart. , 1985, Science.

[409]  F. Murad,et al.  Role of cyclic‐GMP in Relaxations of Vascular mooth Muscle , 1985, Journal of cardiovascular pharmacology.

[410]  T. Beardsley.  Premature death? , 1985, Nature.

[411]  R. Sharma,et al.  Demonstration of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by monoclonal antibodies. , 1984, The Journal of biological chemistry.

[412]  U. Ackermann,et al.  Cardiovascular effects of atrial extracts in anesthetized rats. , 1984, Canadian journal of physiology and pharmacology.

[413]  J. Laragh,et al.  Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide , 1984, Nature.

[414]  J. Rapp,et al.  Inhibition of aldosterone production by an atrial extract. , 1984, Science.

[415]  Robert M. Rapoport,et al.  Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation , 1983, Nature.

[416]  R. Myerburg,et al.  Amrinone Relaxes Potassium‐Induced Contracture of Failing Right Ventricular Muscle of Cats , 1983, Journal of cardiovascular pharmacology.

[417]  M. Edelstein,et al.  Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[418]  F. Murad,et al.  Agonist‐Induced Endothelium‐Dependent Relaxation in Rat Thoracic Aorta May Be Mediated through cGMP , 1983, Circulation research.

[419]  F. Hofmann,et al.  cGMP‐dependent protein kinase decreases calcium sensitivity of skinned cardiac fibers , 1982, FEBS letters.

[420]  A. J. Bold.  Atrial Natriuretic Factor of the Rat Heart. Studies on Isolation and Properties , 1982 .

[421]  R. Furchgott,et al.  Role of endothelial cells in relaxation of isolated arteries by bradykinin. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[422]  M. Mumby,et al.  Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. , 1982, The Journal of biological chemistry.

[423]  I. Cobden,et al.  初期食道静脈りゅう治療におけるテルイプレシン(グリプレシン)とバソプレシンの比較試験 , 1982 .

[424]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[425]  G. McClellan,et al.  Calcium sensitivity of the contractile system and phosphorylation of troponin in hyperpermeable cardiac cells , 1980, The Journal of general physiology.

[426]  日高 弘義,et al.  血小板 cAMP phosphodiesterase の選択的阻害剤について , 1980 .

[427]  D. Blumenthal,et al.  Phosphorylation of cardiac troponin by guanosine 3':5'-monophosphate-dependent protein kinase. , 1978, The Journal of biological chemistry.

[428]  F. Murad,et al.  Effects of sodium nitroprusside, nitroglycerin, and sodium azide on levels of cyclic nucleotides and mechanical activity of various tissues. , 1977, Journal of cyclic nucleotide research.

[429]  F. Murad,et al.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[430]  G. Schultz,et al.  Sodium nitroprusside and other smooth muscle-relaxants increase cyclic GMP levels in rat ductus deferens , 1977, Nature.

[431]  M. Melicow,et al.  Isolation of adenosine 3', 5'-monophosphate and guanosine 3', 5'-monophosphate from rat urine. , 1963, Biochemical and biophysical research communications.

[432]  Koréneková,et al.  Effects of Sodium , 2022 .